Literature DB >> 32773407

BETs that cover the spread from acquired to heritable heart failure.

Michael Alexanian1, Saptarsi M Haldar1,2,3.   

Abstract

Heart failure (HF) with reduced contractile function is a common and lethal syndrome in which the heart cannot pump blood to adequately meet bodily demands, resulting in high mortality despite the current standard of care. In modern societies, the most common drivers of HF are ischemic heart disease and hypertension. However, in a substantial subset of cases, patients present with dilated and poorly contracting hearts without evidence of common inciting stressors, a syndrome called dilated cardiomyopathy (DCM). Genome sequencing has identified a host of deleterious germline variants in key cardiomyocyte genes as causes of heritable DCM, including mutations in LMNA, which encodes the nuclear lamina-associated protein lamin A/C. In this issue of the JCI, Auguste et al. generate a mouse model of DCM in which they delete Lmna in cardiomyocytes and discover that bromodomain and extraterminal (BET) protein activation is a druggable epigenetic mechanism of disease pathogenesis in this heritable HF syndrome.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32773407      PMCID: PMC7456232          DOI: 10.1172/JCI140304

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy.

Authors:  Andrew Antolic; Hiroko Wakimoto; Zhe Jiao; Joshua M Gorham; Steven R DePalma; Madeleine E Lemieux; David A Conner; Da Young Lee; Jun Qi; Jonathan G Seidman; James E Bradner; Jonathan D Brown; Saptarsi M Haldar; Christine E Seidman; Michael A Burke
Journal:  JCI Insight       Date:  2020-08-06

2.  NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis.

Authors:  Jonathan D Brown; Charles Y Lin; Qiong Duan; Gabriel Griffin; Alexander Federation; Ronald M Paranal; Steven Bair; Gail Newton; Andrew Lichtman; Andrew Kung; Tianlun Yang; Hong Wang; Francis W Luscinskas; Kevin Croce; James E Bradner; Jorge Plutzky
Journal:  Mol Cell       Date:  2014-09-25       Impact factor: 17.970

Review 3.  Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors.

Authors:  Oliver Bechter; Patrick Schöffski
Journal:  Pharmacol Ther       Date:  2020-01-11       Impact factor: 12.310

4.  Epigenetic therapies in heart failure.

Authors:  Michael Alexanian; Arun Padmanabhan; Timothy A McKinsey; Saptarsi M Haldar
Journal:  J Mol Cell Cardiol       Date:  2019-04-13       Impact factor: 5.000

5.  Suppression of inflammation by a synthetic histone mimic.

Authors:  Edwige Nicodeme; Kate L Jeffrey; Uwe Schaefer; Soren Beinke; Scott Dewell; Chun-Wa Chung; Rohit Chandwani; Ivan Marazzi; Paul Wilson; Hervé Coste; Julia White; Jorge Kirilovsky; Charles M Rice; Jose M Lora; Rab K Prinjha; Kevin Lee; Alexander Tarakhovsky
Journal:  Nature       Date:  2010-11-10       Impact factor: 49.962

6.  BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure.

Authors:  Qiming Duan; Sarah McMahon; Priti Anand; Hirsh Shah; Sean Thomas; Hazel T Salunga; Yu Huang; Rongli Zhang; Aarathi Sahadevan; Madeleine E Lemieux; Jonathan D Brown; Deepak Srivastava; James E Bradner; Timothy A McKinsey; Saptarsi M Haldar
Journal:  Sci Transl Med       Date:  2017-05-17       Impact factor: 17.956

7.  BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C-deficient mice.

Authors:  Gaelle Auguste; Leila Rouhi; Scot J Matkovich; Cristian Coarfa; Matthew J Robertson; Grazyna Czernuszewicz; Priyatansh Gurha; Ali J Marian
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

8.  BET acetyl-lysine binding proteins control pathological cardiac hypertrophy.

Authors:  Jessica I Spiltoir; Matthew S Stratton; Maria A Cavasin; Kim Demos-Davies; Brian G Reid; Jun Qi; James E Bradner; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2013-08-09       Impact factor: 5.000

9.  Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy.

Authors:  Francesco Mazzarotto; Upasana Tayal; Rachel J Buchan; William Midwinter; Alicja Wilk; Nicola Whiffin; Risha Govind; Erica Mazaika; Antonio de Marvao; Timothy J W Dawes; Leanne E Felkin; Mian Ahmad; Pantazis I Theotokis; Elizabeth Edwards; Alexander Y Ing; Kate L Thomson; Laura L H Chan; David Sim; A John Baksi; Antonis Pantazis; Angharad M Roberts; Hugh Watkins; Birgit Funke; Declan P O'Regan; Iacopo Olivotto; Paul J R Barton; Sanjay K Prasad; Stuart A Cook; James S Ware; Roddy Walsh
Journal:  Circulation       Date:  2020-01-27       Impact factor: 29.690

10.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

View more
  1 in total

1.  BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes.

Authors:  Arun Padmanabhan; Michael Alexanian; Ricardo Linares-Saldana; Rajan Jain; Deepak Srivastava; Bárbara González-Terán; Gaia Andreoletti; Yu Huang; Andrew J Connolly; Wonho Kim; Austin Hsu; Qiming Duan; Sarah A B Winchester; Franco Felix; Juan A Perez-Bermejo; Qiaohong Wang; Li Li; Parisha P Shah; Saptarsi M Haldar
Journal:  Circulation       Date:  2020-10-23       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.